MBX Biosciences Inc (MBX) saw an uptrend of 11.39% in the recent trading with $14.72 being its most recent. The current price level -46.49% lower than the highest price of $27.50 marked by the stock while trading over the past 52-weeks, whereas it is 206.12% higher than the lowest price of $4.81 the company dropped to over past 52-weeks. The latest news story.MBX appeared in (GlobeNewswire) under the title “MBX Biosciences Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights”.
Squeezing the time span to 30 day period shows us the stock is currently trading -7.69% below one month high and is +45.54% above of the lowest during that time. Looking into the simple moving average, MBX Biosciences Inc (MBX)’s stock stands at a SMA-50 of $12.22 while that of 5-day is reading $12.93.
Daily rise and fall of price influence many of the traders, and in order to overcome the fluctuating effect of that and to watch the stock closely, traders focus more.stock’s 200-day moving average. At various points in trading activity, investors are more likely to be making use of that measure as a strong indicator in figuring out their support and resistance levels, and MBX’s SMA-200 as of now is $13.05.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.00 for the stock.
MBX Biosciences Inc Earnings – What Happened With MBX
Coming around sales and income figures.MBX Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor. MBX Biosciences Inc (MBX) last released financial results for the quarter that ended 9/30/2024, posting a surprise factor of -2.29% for net revenue.
MBX – MBX Biosciences Inc Stock Earnings Estimates
The perspective of MBX Biosciences Inc (NASDAQ:MBX)’s current quarter earnings identifies that analysts are in consensus over the estimate of -2.72 for stock’s EPS in the current quarter. MBX Biosciences Inc (MBX) last released financial results for the quarter that ended 9/30/2024, posting a surprise factor of -2.29% for net revenue. Company’s EPS for the last quarter was -2.78.
MBX Biosciences Inc – Insider Activity and Holdings
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 33.59 million. MBX does have institutional investors; and they hold 57.10% of the stock.
Key Metrics forMBX
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, MBX Biosciences Inc has a debt to equity ratio of 0.00.
Technical Analysis of MBX Biosciences Inc (NASDAQ:MBX) stock
To comprehend better with the trade moves and investors’ behavior, exploring the short, medium and long term technical indicators along with average volume of a stock is an effective way to make use of. When looking into those indicators for MBX Biosciences Inc (MBX), we notice that the stock’s 20-day average volume is at 525,020 shares and 100% of short term indicators are suggesting the stock as Buy. Medium term indicators at an average of 50% are spotting the stock at Buy with its 50-day average volume of 415,648 shares. And to end, MBX’s 100-day average volume is 357,944 shares with 50% of the long-term indicators pointing towards Buy for the stock.
